La estadounidense pharmaceutical Eli Lilly recorded a net profit of 5,581.7 million dollars in 2021, which amounts to a 10% discount compared to the previous ownership, according to the company’s Jewers.
The company’s increments between January and December rose to 28,318.4 million dollars, up 15% over 2020.
From this figure, the treatment against diabetes Trulicity if the product is sold as the best-selling, with 6,471.9 million dollars, 28% more, while the substitute for the insulin Humalog increased 7%, up to 2,453 million dollars.
The sales of anti-collateral treatment against Covid-19 will result in a billing of 2,239.2 million dollars, which means multiply by 2.6 the previous year’s records.
The cost of products sold during the acquisition is 7,312.8 million dollars, 33% more, while marketing, sales and administrative guests advance 5%, up to 6,431.6 million dollars. The research and development party (I + D) increased by 15%, amounting to 7,025.9 million dollars.
Only in the quarter of the year, the net benefit of Eli Lilly of 1,726.1 million dollars, an 18% decrease. Between October and December, the laboratory billed 8,000 million dollars, an 8% more.
erp
Reference-www.eleconomista.com.mx